Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus, AAV), Non-viral (Electroporation, Gene Gun)), Method (In-Vivo, In-vitro), Application, (Gene Therapy, Research) - Global Forecast to 2029
세계의 유전자 도입 기술 시장 규모는 2024년 37억 3,000만 달러에서 2029년 59억 3,000만 달러를 돌파하며 연평균 9.7%의 높은 성장률을 나타낼 것으로 예상됩니다.
맞춤형 의료에 대한 수요 증가와 세포 및 유전자 치료의 발전은 이 시장의 성장과 확대에 지속적으로 기여하고 있습니다. 또한, 백신 개발 및 암 면역 요법에서 유전자 도입 기술의 적용이 증가하면서 이 부문의 성장을 가속하고 있습니다.
| 조사 범위 |
| 조사 대상연도 |
2022-2029년 |
| 기준연도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 검토 단위 |
금액(미화) |
| 부문별 |
제품별, 모드별, 기법별, 용도별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동/아프리카 |
모드별로 유전자 도입 기술 시장은 바이러스 벡터와 비바이러스 벡터로 세분화됩니다. 바이러스 벡터 부문은 레트로바이러스, 아데노바이러스, 아데노 관련 바이러스(AAV), 기타 바이러스 벡터로 나뉩니다. 바이러스 벡터 부문은 우수한 안전성 및 유효성 프로파일, 최소한의 면역원성, AAV 엔지니어링의 발전으로 인해 2023년 바이러스 벡터 부문이 시장을 장악할 것으로 예상됩니다.
유전자 도입 기술 시장의 응용 분야는 연구, 치료, 기타로 구분됩니다. 연구 분야는 신약개발과 기타 연구 분야로 나뉩니다. 마찬가지로 치료용은 다시 유전자 치료, 세포 치료, 백신, 기타 치료용 등으로 나뉩니다. 치료용은 개량형 아데노부수체 바이러스(AAV), 렌티바이러스 벡터 등 유전자 도입 기술의 발전과 심혈관질환, 신경질환, 대사성 질환에 대한 유전자 치료의 적용 확대에 따라 이 분야에서 압도적인 점유율을 차지하고 있습니다.
지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분되며, 2023년 유전자 재조합 기술 시장은 북미가 지배적인 시장이며, 예측 기간 동안에도 북미의 지배력이 지속될 것으로 보입니다. 이 지역에는 유전자 재조합 기술 기업의 유력한 시장 진출기업들이 존재하며, Thermo Fisher Scientific Inc.(미국), Danaher Corporation(미국), Merck KGaA(독일) 등 유전자 재조합 기술 제조업체의 탄탄한 기반이 시장 성장을 가속하는 두드러진 요인으로 작용하고 있습니다. 시장 성장을 가속하는 요인으로 작용하고 있습니다.
이 보고서는 세계의 유전자 도입 기술 시장을 조사했으며, 제품별/모드별/기법별/용도별/지역별 동향, 시장 진출기업 프로파일 등을 정리한 보고서입니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
제5장 시장 개요
- 서론
- 시장 역학
- 생태계 분석
- 기술 분석
- 가격 분석
- 밸류체인 분석
- 공급망 분석
- 특허 분석
- 무역 분석
- 2024-2025년 주요 컨퍼런스 및 이벤트
- 규제 상황
- Porter의 Five Forces 분석
- 주요 이해관계자와 구입 기준
- 투자와 자금조달 시나리오
- 고객의 비즈니스에 영향을 미치는 동향/혼란
- AI/생성형 AI가 유전자 도입 기술 시장에 미치는 영향
제6장 유전자 도입 기술 시장, 제품별
제7장 유전자 도입 기술 시장, 모드별
- 서론
- 바이러스 벡터
- 비바이러스 벡터
- 물리적 방법
제8장 유전자 도입 기술 시장, 방법별
제9장 유전자 도입 기술 시장, 용도별
제10장 유전자 도입 기술 시장, 최종사용자별
- 서론
- 제약 기업 및 바이오테크놀러지 기업
- 학술연구기관
- 기타
제11장 유전자 도입 기술 시장, 지역별
- 서론
- 북미
- 유럽
- 유럽 : 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 아시아태평양
- 아시아태평양 : 거시경제 전망
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타
- 라틴아메리카
- 라틴아메리카 : 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동
- 아프리카
- 시장 성장을 지지하는 치료제로서의 유전자 도입 기술에의 중점 증가
- 아프리카 거시경제 전망
제12장 경쟁 구도
- 개요
- 주요 시장 진출기업의 전략/강점
- 매출 분석
- 시장 점유율 분석
- 기업 평가 매트릭스 : 주요 시장 진출기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 기업 평가와 재무 지표
- 브랜드/제품 비교
- 경쟁 시나리오
제13장 기업 개요
- 주요 시장 진출기업
- THERMO FISHER SCIENTIFIC INC.
- DANAHER CORPORATION
- MERCK KGAA
- BIO-RAD LABORATORIES, INC.
- AGILENT TECHNOLOGIES, INC.
- REVVITY
- QIAGEN
- GENSCRIPT
- TAKARA BIO INC.
- PROMEGA CORPORATION
- BIO-TECHNE
- LONZA
- OXFORD BIOMEDICA PLC
- SARTORIUS AG
- MAXCYTE
- 기타 기업
- CELL BIOLABS, INC.
- GENTARGET INC.
- ORIGENE TECHNOLOGIES, INC.
- ALTOGEN BIOSYSTEMS
- OZ BIOSCIENCES
- GENECOPOEIA, INC.
- CREATIVE BIOLABS
- SYNBIO TECHNOLOGIES LLC
- SYSTEM BIOSCIENCES, LLC
- VECTORBUILDER INC.
제14장 부록
LSH
The global gene transfer technologies market is projected to surpass USD 5.93 billion in 2029 from USD 3.73 billion in 2024, with a significant CAGR of 9.7%. Increasing demand for personalized medicines, along with advancements in cell and gene therapies, continues to grow and contribute to a rise in this market. In addition, the increased application of gene transfer technologies in vaccine development and cancer immunotherapy boosts the segmental growth.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Product, Mode, Method, Application and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"The viral vector gene transfer technologies segment accounted for the largest share in 2023."
On the basis of mode, the gene transfer technologies market is further segmented into viral vector and non-viral vector. The viral vector segment is retrovirus, adenovirus, adeno associated virus (AAV) and other virus vector. The viral vector segment dominated the market in 2023, owing to superior safety and efficacy profile, minimal immunogenicity and advancements in AAV engineering.
"By application, the therapeutic application segment accounted for the largest share in the gene transfer technologies market."
The application segment in the gene transfer technologies market is segmented into research application, therapeutic application and applications. The research application is segmented into drug discovery & development and other research application. Similarly the therapeutic application further divided into gene therapy, cell therapy, vaccines and other therapeutic application. The therapeutic application dominated the segment owing to advancements in gene transfer technologies, such as improved adeno-associated virus (AAV) & lentiviral vector and expanding application of gene therapy in cardiovascular, neurological and metabolic diseases.
"North America: the largest share of the gene transfer technologies market"
By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the gene transfer technologies market in 2023 and likely continue dominance during the forecast period. Presence of dominant market players in gene transfer technologies companies in the region, strong base of gene transfer technologies manufacturers such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany) are some of the prominent factors acerating market growth.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the gene transfer technologies market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany), Bio-Rad Laboratories Inc. (US), Revvity (US), Agilent Technologies, Inc. (US), Genscript (US), Bio-Techne (US), Lonza (Switzerland), Takara Bio, Inc. (Japan), Promega Corporation (US), Oxford Biomedica plc (UK) and MaxCyte (US) ) are some of the major players operating in the gene transfer technologies market.
Research Coverage:
This research report categorizes the gene transfer technologiess market product (instruments, consumables, reagents,kits & assays and other products), mode (viral vector and non viral vector), method (ex vivo, in vivo and in vitro), application (research, therapeutic and orther application) end user (pharmaceutical & biotechnology companies, academic & research institutes and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the gene transfer technologiess market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the gene transfer technologies market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene transfer technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing demand for personalized medicines and cell & gene therapies, Increased investments in gene therapy research, Expanding applications in vaccine development & cancer immunotherapy), restraints (High costs of gene transfer systems), opportunities (Advancements in gene editing technologies and nanotechnology, Integration with digital technologies such as AI and ML) and Challenges (Scalability of production).
- Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for gene transfer technologies.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene transfer technologies market
- Competitive Assessment: Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany) and among others in the market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET ESTIMATION METHODOLOGY
- 2.2.1 MARKET ESTIMATION
- 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
- 2.2.3 TOP-DOWN APPROACH
- 2.3 MARKET GROWTH RATE PROJECTION
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 GENE DELIVERY TECHNOLOGIES MARKET OVERVIEW
- 4.2 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION (2023)
- 4.3 GENE DELIVERY TECHNOLOGIES MARKET SHARE, BY MODE, 2024 VS. 2029
- 4.4 GENE DELIVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing demand for personalized medicine and cell & gene therapies
- 5.2.1.2 Increased investments in gene therapy research
- 5.2.1.3 Expanding applications in vaccine development & cancer immunotherapy
- 5.2.2 RESTRAINTS
- 5.2.2.1 High costs of gene delivery systems
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Advancements in gene editing technologies & nanotechnology
- 5.2.3.2 Integration with digital technologies such as AI & ML
- 5.2.4 CHALLENGES
- 5.2.4.1 Scalability of production
- 5.3 ECOSYSTEM ANALYSIS
- 5.3.1 PRODUCT PROVIDERS
- 5.3.2 END USERS
- 5.3.3 REGULATORY BODIES
- 5.4 TECHNOLOGY ANALYSIS
- 5.4.1 KEY TECHNOLOGIES
- 5.4.1.1 Microinjection
- 5.4.1.2 Electroporation
- 5.4.1.3 Sonoporation
- 5.4.2 COMPLEMENTARY TECHNOLOGIES
- 5.4.2.1 Gene editing technologies
- 5.4.2.2 Bioinformatics and computational tools
- 5.4.3 ADJCENT TECHNOLOGIES
- 5.4.3.1 Nanotechnology and nano-carriers
- 5.5 PRICING ANALYSIS
- 5.5.1 AVERAGE SELLING PRICE TREND OF REAGENTS/CONSUMABLES, BY KEY PLAYER
- 5.5.2 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 SUPPLY CHAIN ANALYSIS
- 5.8 PATENT ANALYSIS
- 5.9 TRADE ANALYSIS
- 5.9.1 IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)
- 5.9.2 EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)
- 5.10 KEY CONFERENCES AND EVENTS, 2024-2025
- 5.11 REGULATORY LANDSCAPE
- 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.11.2 REGULATORY FRAMEWORK
- 5.11.2.1 North America
- 5.11.2.2 Europe
- 5.11.2.3 Asia Pacific
- 5.11.2.4 Rest of the World
- 5.12 PORTER'S FIVE FORCES ANALYSIS
- 5.12.1 THREAT OF NEW ENTRANTS
- 5.12.2 THREAT OF SUBSTITUTES
- 5.12.3 BARGAINING POWER OF BUYERS
- 5.12.4 BARGAINING POWER OF SUPPLIERS
- 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.13.1 KEY STAKEHOLDERS
- 5.13.2 BUYING CRITERIA
- 5.14 INVESTMENT AND FUNDING SCENARIO
- 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.16 IMPACT OF AI/GEN AI ON GENE DELIVERY TECHNOLOGIES MARKET
6 GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 REAGENTS, KITS, AND ASSAYS
- 6.2.1 INCREASING DEMAND FOR TRANSFECTION AND GENE EDITING TOOLS TO DRIVE MARKET GROWTH
- 6.3 CONSUMABLES
- 6.3.1 RISING R&D ACTIVITY TO SUPPORT DEMAND GROWTH
- 6.4 INSTRUMENTS
- 6.4.1 INCREASING ADOPTION OF ELECTROPORATION DEVICES TO DRIVE MARKET
- 6.5 OTHER PRODUCTS
7 GENE DELIVERY TECHNOLOGIES MARKET, BY MODE
- 7.1 INTRODUCTION
- 7.2 VIRAL VECTORS
- 7.2.1 RETROVIRUSES
- 7.2.1.1 Lentiviruses
- 7.2.1.1.1 Rising disease incidence to drive market
- 7.2.1.2 Other retroviruses
- 7.2.2 ADENOVIRUSES
- 7.2.2.1 Expansion of vaccination programs to propel market growth
- 7.2.3 ADENO-ASSOCIATED VIRUSES
- 7.2.3.1 Low immunogenicity of AAV vectors to support adoption
- 7.2.4 OTHER VIRAL VECTORS
- 7.3 NON-VIRAL VECTORS
- 7.3.1 CHEMICAL METHODS
- 7.3.2 LIPOSOME-MEDIATED
- 7.3.2.1 High efficiency and compatibility to drive market
- 7.3.3 CALCIUM PHOSPHATE
- 7.3.3.1 Increasing R&D in cell-based therapies to propel market growth
- 7.3.4 DEAE-DEXTRAN
- 7.3.4.1 Simplicity and cost-effectiveness to support adoption
- 7.3.5 CATIONIC POLYMERS
- 7.3.5.1 Advancements in cationic polymer technology to drive market
- 7.3.6 OTHER CHEMICAL METHODS
- 7.4 PHYSICAL METHODS
- 7.4.1 ELECTROPORATION
- 7.4.1.1 Rising demand for effective cell transfection technologies to drive market
- 7.4.2 MICROINJECTION
- 7.4.2.1 High accuracy and control and potential for tailored delivery to drive market
- 7.4.3 GENE GUNS
- 7.4.3.1 High efficiency of gene guns in transfecting various cell types to drive market
- 7.4.4 OTHER PHYSICAL METHODS
8 GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD
- 8.1 INTRODUCTION
- 8.2 IN VIVO
- 8.2.1 EMERGENCE OF MRNA-BASED VACCINES TO PROPEL IN VIVO GENE DELIVERY APPLICATIONS
- 8.3 EX VIVO
- 8.3.1 SUCCESSFUL COMMERCIALIZATION OF CAR T-CELL THERAPIES TO DRIVE THE EX VIVO GENE DELIVERY MARKET
- 8.4 IN VITRO
- 8.4.1 DATABASES MAJORLY CONTRIBUTE TO STORING GENE DELIVERY TECHNOLOGIES AND INTEGRATING OTHER OMICS DATABASES.
9 GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION
- 9.1 INTRODUCTION
- 9.2 THERAPEUTIC APPLICATIONS
- 9.2.1 GENE THERAPY
- 9.2.1.1 Increasing demand for personalized medicine to support market growth
- 9.2.2 CELL THERAPY
- 9.2.2.1 Rising government funding to propel market growth
- 9.2.3 VACCINES
- 9.2.3.1 Rising prevalence of infectious diseases to drive market growth
- 9.2.4 OTHER THERAPEUTIC APPLICATIONS
- 9.3 RESEARCH APPLICATIONS
- 9.3.1 DRUG DISCOVERY & DEVELOPMENT
- 9.3.1.1 Increased funding for gene therapy research to drive market growth
- 9.3.1.2 Cancer
- 9.3.1.2.1 Rising investment in cancer research to drive market
- 9.3.2 INFECTIOUS DISEASES
- 9.3.2.1 Rising incidence of infectious disease to drive market growth
- 9.3.3 GENETIC & NEUROLOGICAL DISORDERS
- 9.3.3.1 Rising burden of disorders to drive market
- 9.3.4 AUTOIMMUNE DISEASES
- 9.3.4.1 Growing prevalence of autoimmune disorders to ensure demand for therapeutic solutions
- 9.3.5 OTHER DISEASES
- 9.3.6 OTHER RESEARCH APPLICATIONS
- 9.4 OTHER APPLICATIONS
10 GENE DELIVERY TECHNOLOGIES MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET
- 10.3 ACADEMIC & RESEARCH INSTITUTES
- 10.3.1 INCREASING R&D AND GROWING FUNDING AND PARTNERSHIPS TO PROMOTE MARKET GROWTH
- 10.4 OTHER END USERS
11 GENE DELIVERY TECHNOLOGIES MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 NORTH AMERICA
- 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
- 11.2.2 US
- 11.2.2.1 US to dominate North American market over forecast period
- 11.2.3 CANADA
- 11.2.3.1 Strong infrastructure and availability of funding for biomedical research to support market growth
- 11.3 EUROPE
- 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
- 11.3.2 GERMANY
- 11.3.2.1 Germany to hold largest market share in Europe
- 11.3.3 UK
- 11.3.3.1 Increasing government funding to drive market growth
- 11.3.4 FRANCE
- 11.3.4.1 Rising support for genetic research to offer potential growth opportunities
- 11.3.5 ITALY
- 11.3.5.1 Rising R&D and support for gene delivery to drive market
- 11.3.6 SPAIN
- 11.3.6.1 Growing expansion of research centers to stimulate market
- 11.3.7 REST OF EUROPE
- 11.4 ASIA PACIFIC
- 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- 11.4.2 CHINA
- 11.4.2.1 Increasing R&D expenditure to drive market growth
- 11.4.3 JAPAN
- 11.4.3.1 Rising research into precision medicine to support market growth
- 11.4.4 INDIA
- 11.4.4.1 Strong research base and rising FDI in pharma sector to support market growth
- 11.4.5 SOUTH KOREA
- 11.4.5.1 Alliances & investments in research to drive market
- 11.4.6 AUSTRALIA
- 11.4.6.1 Increasing focus on precision medicine to offer significant growth opportunities
- 11.4.7 REST OF ASIA PACIFIC
- 11.5 LATIN AMERICA
- 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
- 11.5.2 BRAZIL
- 11.5.2.1 Brazil to hold largest market share in LATAM
- 11.5.3 MEXICO
- 11.5.3.1 Strong pharmaceutical industry and increased government support to augment market growth
- 11.5.4 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST
- 11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
- 11.6.2 GCC COUNTRIES
- 11.6.2.1 Saudi Arabia
- 11.6.2.1.1 Increasing government investments in healthcare and growing pharmaceuticals industry to support market
- 11.6.2.2 UAE
- 11.6.2.2.1 Growing R&D expenditure and infrastructural development to drive market
- 11.6.2.3 Rest of GCC Countries
- 11.6.3 REST OF MIDDLE EAST
- 11.7 AFRICA
- 11.7.1 RISING EMPHASIS ON GENE DELIVERY TECHNOLOGIES FOR THERAPEUTICS TO SUPPORT MARKET GROWTH
- 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
- 12.1 OVERVIEW
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GENE DELIVERY TECHNOLOGIES MARKET
- 12.3 REVENUE ANALYSIS
- 12.4 MARKET SHARE ANALYSIS
- 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 12.5.1 STARS
- 12.5.2 EMERGING LEADERS
- 12.5.3 PERVASIVE PLAYERS
- 12.5.4 PARTICIPANTS
- 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 12.5.5.1 Company footprint
- 12.5.5.2 Region footprint
- 12.5.5.3 Product footprint
- 12.5.5.4 Method footprint
- 12.5.5.5 Application footprint
- 12.5.5.6 End-user footprint
- 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 12.6.1 PROGRESSIVE COMPANIES
- 12.6.2 RESPONSIVE COMPANIES
- 12.6.3 DYNAMIC COMPANIES
- 12.6.4 STARTING BLOCKS
- 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 12.7 COMPANY VALUATION & FINANCIAL METRICS
- 12.7.1 FINANCIAL METRICS
- 12.7.2 COMPANY VALUATION
- 12.8 BRAND/PRODUCT COMPARISON
- 12.9 COMPETITIVE SCENARIO
- 12.9.1 PRODUCT LAUNCHES
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
13 COMPANY PROFILES
- 13.1 KEY PLAYERS
- 13.1.1 THERMO FISHER SCIENTIFIC INC.
- 13.1.1.1 Business overview
- 13.1.1.2 Products/Services/Solutions offered
- 13.1.1.3 Recent developments
- 13.1.1.3.1 Product launches
- 13.1.1.3.2 Expansions
- 13.1.1.4 MnM view
- 13.1.1.4.1 Key strengths
- 13.1.1.4.2 Strategic choices
- 13.1.1.4.3 Weaknesses and competitive threats
- 13.1.2 DANAHER CORPORATION
- 13.1.2.1 Business overview
- 13.1.2.2 Products/Services/Solutions offered
- 13.1.2.3 Recent developments
- 13.1.2.3.1 Product launches
- 13.1.2.3.2 Deals
- 13.1.2.3.3 Expansions
- 13.1.2.4 MnM view
- 13.1.2.4.1 Key strengths
- 13.1.2.4.2 Strategic choices
- 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 MERCK KGAA
- 13.1.3.1 Business overview
- 13.1.3.2 Products/Services/Solutions offered
- 13.1.3.3 Recent developments
- 13.1.3.3.1 Deals
- 13.1.3.3.2 Expansions
- 13.1.3.4 MnM view
- 13.1.3.4.1 Key strengths
- 13.1.3.4.2 Strategic choices
- 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 BIO-RAD LABORATORIES, INC.
- 13.1.4.1 Business overview
- 13.1.4.2 Products/Services/Solutions offered
- 13.1.5 AGILENT TECHNOLOGIES, INC.
- 13.1.5.1 Business overview
- 13.1.5.2 Products/Services/Solutions offered
- 13.1.5.3 Recent developments
- 13.1.6 REVVITY
- 13.1.6.1 Business overview
- 13.1.6.2 Products/Services/Solutions offered
- 13.1.6.3 Recent developments
- 13.1.6.3.1 Product launches
- 13.1.6.3.2 Deals
- 13.1.7 QIAGEN
- 13.1.7.1 Business overview
- 13.1.7.2 Products/Services/Solutions offered
- 13.1.8 GENSCRIPT
- 13.1.8.1 Business overview
- 13.1.8.2 Products/Services/Solutions offered
- 13.1.8.3 Recent developments
- 13.1.9 TAKARA BIO INC.
- 13.1.9.1 Business overview
- 13.1.9.2 Products/Services/Solutions offered
- 13.1.9.3 Recent developments
- 13.1.9.3.1 Product launches
- 13.1.9.3.2 Deals
- 13.1.10 PROMEGA CORPORATION
- 13.1.10.1 Business overview
- 13.1.10.2 Products/Services/Solutions offered
- 13.1.11 BIO-TECHNE
- 13.1.11.1 Business overview
- 13.1.11.2 Products/Services/Solutions offered
- 13.1.11.3 Recent developments
- 13.1.11.3.1 Product launches
- 13.1.12 LONZA
- 13.1.12.1 Business overview
- 13.1.12.2 Products/Services/Solutions offered
- 13.1.12.3 Recent developments
- 13.1.12.3.1 Product launches
- 13.1.12.3.2 Deals
- 13.1.13 OXFORD BIOMEDICA PLC
- 13.1.13.1 Business overview
- 13.1.13.2 Products/Services/Solutions offered
- 13.1.13.3 Recent developments
- 13.1.13.3.1 Product launches
- 13.1.13.3.2 Deals
- 13.1.13.3.3 Other developments
- 13.1.14 SARTORIUS AG
- 13.1.14.1 Business overview
- 13.1.14.2 Products/Services/Solutions offered
- 13.1.14.3 Recent developments
- 13.1.14.3.1 Product launches
- 13.1.14.3.2 Deals
- 13.1.15 MAXCYTE
- 13.1.15.1 Business overview
- 13.1.15.2 Products/Services/Solutions offered
- 13.1.15.3 Recent developments
- 13.2 OTHER PLAYERS
- 13.2.1 CELL BIOLABS, INC.
- 13.2.2 GENTARGET INC.
- 13.2.3 ORIGENE TECHNOLOGIES, INC.
- 13.2.4 ALTOGEN BIOSYSTEMS
- 13.2.5 OZ BIOSCIENCES
- 13.2.6 GENECOPOEIA, INC.
- 13.2.7 CREATIVE BIOLABS
- 13.2.8 SYNBIO TECHNOLOGIES LLC
- 13.2.9 SYSTEM BIOSCIENCES, LLC
- 13.2.10 VECTORBUILDER INC.
14 APPENDIX
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
